Alliance Global Partners Lowers Barinthus Biotherapeutics (NASDAQ:BRNS) Price Target to $9.50

Barinthus Biotherapeutics (NASDAQ:BRNS) had its price objective lowered by Alliance Global Partners from $11.00 to $9.50 in a research note released on Tuesday, Benzinga reports. Alliance Global Partners currently has a buy rating on the stock.

A number of other equities analysts have also recently issued reports on BRNS. William Blair reiterated an outperform rating on shares of Barinthus Biotherapeutics in a research report on Thursday, June 13th. HC Wainwright reissued a buy rating and set a $5.00 price objective on shares of Barinthus Biotherapeutics in a report on Monday, August 12th. Finally, Barclays lowered their target price on Barinthus Biotherapeutics from $7.00 to $3.00 and set an overweight rating for the company in a report on Thursday, June 13th.

Barinthus Biotherapeutics Price Performance

Shares of BRNS opened at $1.25 on Tuesday. The firm has a 50 day simple moving average of $1.47 and a two-hundred day simple moving average of $2.16. The company has a market cap of $48.79 million, a P/E ratio of -0.68 and a beta of -0.52. Barinthus Biotherapeutics has a one year low of $1.21 and a one year high of $5.10.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.01). On average, analysts expect that Barinthus Biotherapeutics will post -1.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. M&G Plc bought a new position in shares of Barinthus Biotherapeutics during the second quarter worth about $7,276,000. Alphabet Inc. acquired a new stake in Barinthus Biotherapeutics during the 2nd quarter valued at approximately $2,119,000. Catalina Capital Group LLC bought a new position in Barinthus Biotherapeutics during the 2nd quarter worth approximately $25,000. Ipswich Investment Management Co. Inc. acquired a new position in shares of Barinthus Biotherapeutics in the 2nd quarter worth approximately $32,000. Finally, BlueCrest Capital Management Ltd bought a new stake in shares of Barinthus Biotherapeutics in the 1st quarter valued at $1,292,000. 25.20% of the stock is owned by institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.